Excellent response, low TRM and good survival in patients with therapy-refractory aGvHD after treatment with potency-defined doses of MSCs generated from a serum-free MSC-BANK of pooled BM-MNCS from multiple healthy donors

Bader, Peter; Kuçi, Zyrafete; Bakhtiar, Shahrzad; Basu, Oliver; Bug, Gesine; Dennis, Mike; Greil, Johann; Kállay, Krisztián; Lang, Peter; Luccini, Giovanna; Pol, Raj; Schulz, Ansgar; Sykora, Karl Walther; Luettichau, Irene von; Jarisch, Andrea; Soerensen, Jan; Salzmann, E; Seifried, Erhard; Klingebiel, Thomas; Boenig, Halvard; Kuçi, Selim

doi:10.1016/j.jcyt.2017.03.023

Search citation statements

Order By: Relevance

Paper Sections

Select...

Advantages Of Using a Pooled Human Bmmsc (Phbmmsc Stempeuce1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2020

Publication Types

Select...

Book1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the contrary, a mesenchymal end product (MEP) made by pooling BMMNCs from eight donors resulted in a cell population that consistently suppressed an MLR in vitro [39]. Subsequently, they went on to conduct a multicentric SR-aGvHD clinical trial in 51 children and 18 adults using MEP/MSC Frankfurt am Main (MSC-FFM, Obnitix®) cells and observed 83% overall response (complete response, 32%; partial response, 51%) [40]. At Stempeutics Research Pvt.…”

Section: Advantages Of Using a Pooled Human Bmmsc (Phbmmsc Stempeucementioning

confidence: 99%

The Role of Mesenchymal Stromal Cells in the Management of Osteoarthritis of the Knee

Thej¹,

Gupta²

2020

Update on Mesenchymal and Induced Pluripotent Stem Cells

View full text Add to dashboard Cite

Osteoarthritis (OA) is one of the most common chronic, inflammatory, and degenerative diseases affecting the synovial joints, the hip, and the knee. OA is commonly managed clinically by treating pain with anti-inflammatory medicines using nonsteroidal anti-inflammatory drugs (NSAIDS) or analgesics. In severe OA patients, invasive knee replacement surgery is the last option. Treatment of OA using mesenchymal stromal cells (MSCs) has been widely explored due to their anti-inflammatory properties and chondrogenic differentiation potential. In this chapter, we comprehensively discuss in detail the in vitro OA potency development, OA preclinical studies, and clinical trials conducted using MSCs.

show abstract

Section: Advantages Of Using a Pooled Human Bmmsc (Phbmmsc Stempeucementioning

confidence: 99%

The Role of Mesenchymal Stromal Cells in the Management of Osteoarthritis of the Knee

Thej¹,

Gupta²

2020

Update on Mesenchymal and Induced Pluripotent Stem Cells

View full text Add to dashboard Cite

show abstract

Excellent response, low TRM and good survival in patients with therapy-refractory aGvHD after treatment with potency-defined doses of MSCs generated from a serum-free MSC-BANK of pooled BM-MNCS from multiple healthy donors

Cited by 1 publication

References 0 publications

The Role of Mesenchymal Stromal Cells in the Management of Osteoarthritis of the Knee

The Role of Mesenchymal Stromal Cells in the Management of Osteoarthritis of the Knee

Contact Info

Product

Resources

About